Samar Issa
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Papers in
- Co-authors
- David Simpson (14 shared papers)Peter Wood (12 shared papers)Kathryn S. Kolibaba (10 shared papers)Ian W. Flinn (10 shared papers)David MacDonald (10 shared papers)John M. Burke (10 shared papers)Tim E. Hawkins (9 shared papers)Brad S. Kahl (8 shared papers)
- Journals
- Blood (16 papers)Journal of Clinical Oncology (7 papers)Neuro-Oncology (6 papers)Hematological Oncology (3 papers)Annals of Oncology (2 papers)
- Partner nations
- New ZealandAustraliaUnited States
In The Last Decade
Samar Issa
49 papers receiving 1.6k citations
Samar Issa's Hit Papers
Peers
Comparison fields: 5 of 61
- Genetics 741
- Pathology and Forensic Medicine 1.1k
- Neurology 706
- Oncology 561
- Hematology 103
Countries citing papers authored by Samar Issa
This map shows the geographic impact of Samar Issa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samar Issa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samar Issa more than expected).
Fields of papers citing papers by Samar Issa
This network shows the impact of papers produced by Samar Issa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samar Issa. The network helps show where Samar Issa may publish in the future.
Co-authors
The 25 scholars most cited alongside Samar Issa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Hit paper breakdown → | 2014 | 430 |
| 2 | 2007 | 244 | |
| 3 | 2019 | 179 | |
| 4 | 2019 | 163 | |
| 5 | 2012 | 100 | |
| 6 | 2018 | 69 | |
| 7 | 2019 | 53 | |
| 8 | 2012 | 43 | |
| 9 | 2013 | 37 | |
| 10 | 2020 | 34 | |
| 11 | 2012 | 26 | |
| 12 | 2011 | 23 | |
| 13 | 2012 | 18 | |
| 14 | 2021 | 15 | |
| 15 | 2012 | 14 | |
| 16 | 2016 | 14 | |
| 17 | 2021 | 14 | |
| 18 | 2017 | 13 | |
| 19 | 2021 | 13 | |
| 20 | 2017 | 10 |
About Samar Issa
Samar Issa is a scholar working on Neurology, Genetics, Pathology and Forensic Medicine, Oncology and Hematology, having authored 51 papers that have together received 1.6k indexed citations. Recurring topics across this work include CNS Lymphoma Diagnosis and Treatment (27 papers), Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (17 papers), Chronic Myeloid Leukemia Treatments (7 papers), Glioma Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Genetics (741 citations), Pathology and Forensic Medicine (1.1k citations), Neurology (706 citations), Oncology (561 citations) and Hematology (103 citations). Samar Issa has collaborated with scholars based in New Zealand, Australia and United States. Frequent co-authors include David Simpson, Peter Wood, Kathryn S. Kolibaba, Ian W. Flinn, David MacDonald, John M. Burke, Tim E. Hawkins, Brad S. Kahl, Doreen M. Hallman and Richard van der Jagt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Neuro-Oncology, Hematological Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.